About the group
The Research group of prostate cancer consists of urologists and oncologists (main members) and physicians and scientists from other departments and institutes (associated members), engaged in prostate cancer research at Oslo University Hospital (OUH). Main topic of clinical research is new diagnostic methods, outcomes studies and Quality of Life studies after primary treatment and salvage treatment of prostate cancer.
The main aims for our translational research are detection and validation of new putative biomarkers in tumor tissue, blood and urine. This effort focuses on achieving a more personalized treatment of patients, in order to reduce overdiagnosis and overtreatment of prostate cancer, but also to improve diagnosis and treatment of high-risk prostate cancer.
Ongoing projects
The last year has been an active year for our research group. Main members in the group have authored or coauthored 18 publications about prostate cancer during 2022, the same number as last year.
At the NUF meeting in Helsinki, our group was well represented, and one of our abstract even won the prize for best abstract: “Functional outcomes at 12 months after focal ablation versus radical prostatectomy for intermediate risk prostate cancer. Interim analysis of randomized control trial” presented by ass. professor Eduard Baco.
The randomized double blind study PeP-RALP was launched by PhD student Shivanthe Sivanesan in December. This is a pilot study targeting perioperative stress induced prostate cancer recurrence.
The research registry for prostate cancer is continuously improving; the latest change is inclusion of HIFU patients.
A satisfying trend is that the registry is utilized by increasing numbers of urologist at the department, both in presentations at meetings and congresses and in publications. At the Surgical Fall Meeting last year no other department of urology presented more abstracts than ours.
The SPCG-17 study is recruiting well with 105 included patients at the end of 2022 into active surveillance for low risk and intermediate risk cancer prostate.
Our group is also engaged in upstart of the SPCG 19 study: A randomized, controlled, open-label, prospective, multicenter intervention trial of immediate curative therapy versus conservative treatment in older patients with non-metastatic, high-risk prostate cancer.
Several members in our group have during 2022 been engaged in planning of the new prostate cancer center at Nye DNR.
Cooperation
National
- IMBV, UiO, Fahri Saatcioglu
- Urologisk avd. Ahus
- Urologisk avdeling, St. Olavs sykehus, Helena Bertilsson, May–Britt Tessem
- Kreftforskningsinstituttet, OUS. Kristin Tasken, Alicia Llorente
- Kreftregisteret
International
- Department of Urology, Vivantes Klinikum Am Urban, Berlin, Germany
- Johns Hopkins School of Medicine, USA
- Queen University, Belfast, UK
- Martini Hospital, Hamburg, Germany
- University College Dublin, Irland
- University College of London
Selected Publications
- Is time from diagnosis to radical prostatectomy associated with oncological outcomes? K Aas, SD Fosså, R Kvåle, B Møller, TÅ Myklebust, L Vlatkovic, S Müller, Berge V. World journal of urology, 2019, 37 (8), 1571-1580.
- Hopland OA, Fosså SD, Ottosson F, Brennhovd B, Svindland A, Hole KH, Hernes E, Eri LM, Diep LM, Berge V. Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience. Scand J Urol. 2021 Aug;55(4):287-292. doi: 10.1080/21681805.2021.1946135. Epub 2021 Jul 1.
- Fosså SD, Beyer B, Dahl AA, Aas K, Eri LM, Kvan E, Falk RS, Graefen M, Huland H, Berge V. Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique. Scand J Urol. 2019 Dec;53(6):385-391. doi: 10.1080/21681805.2019.1693625. Epub 2019 Dec 4
- Aas K, Dorothea Fosså S, Åge Myklebust T, Møller B, Kvåle R, Vlatkovic L, Berge V. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study. Cancer Med. 2020 Sep;9(18):6646-6657. doi: 10.1002/cam4.3297. Epub 2020 Aug 4.
- Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ; Focal Therapy Society.Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. doi: 10.1016/j.eururo.2023.06.013. Online ahead of print.PMID: 37419773 Review.
- Tissue distribution of ethanol after intraprostatic injection using a porous needle. Eubank MN, Švihra J Jr, DiBona KC, Sommers M, Oe T, Strnádel J, Miklušica J, Szépe P, Marcinek J, King BJ, Plante MK, Ľupták J, Poulsen MHA, Kida M, Baco E, Švihra J, Zvara P.Front Oncol. 2023 Jan 4;12:1063781. doi: 10.3389/fonc.2022.1063781. eCollection 2022.PMID: 36686794 Free PMC article.
- Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Jacewicz M, Günzel K, Rud E, Sandbæk G, Magheli A, Busch J, Hinz S, Baco E.Lancet Infect Dis. 2022 Oct;22(10):1465-1471. doi: 10.1016/S1473-3099(22)00373-5. Epub 2022 Jul 12.PMID: 35839791 Clinical Trial.
- Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T.JAMA Oncol. 2022 Mar 1;8(3):e216871. doi: 10.1001/jamaoncol.2021.6871. Epub 2022 Mar 17.PMID: 35050303 Free PMC article. Clinical Trial.
- Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU.JAMA Netw Open. 2021 Dec 1;4(12):e2138550. doi: 10.1001/jamanetworkopen.2021.38550.PMID: 34902034